英国范可尼贫血患者接受阿仑单抗-Flu-Cy预处理匹配供者骨髓移植的优异总生存与无慢性GVHD无事件生存
该研究回顾性分析了1999至2018年英国82例范可尼贫血患儿共94次造血干细胞移植,多数采用氟达拉滨-环磷酰胺预处理及阿仑单抗体内T细胞清除。
要点
- 匹配相关或无关供者骨髓移植在范可尼贫血患儿中可获得优异生存。
- 预处理采用Flu-Cy及阿仑单抗与改善5年总生存相关。
- 无MDS或白血病、骨髓来源干细胞及特定CMV血清状态为保护因素。
核心结论
- 匹配相关或无关供者造血干细胞移植在范可尼贫血患儿中确认可获得优异结局。
研究设计与样本
- 回顾性分析1999至2018年英国82例范可尼贫血患儿共94次造血干细胞移植。
主要发现
- 多因素分析中,无MDS或白血病、骨髓作为干细胞来源、CMV血清状态非+/-及Flu-Cy预处理为5年总生存保护因素。
临床怎么用
- 对范可尼贫血患儿优先选择匹配相关或无关供者进行骨髓移植,并考虑Flu-Cy预处理联合阿仑单抗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Haematopoietic stem cell transplantation (HSCT) remains the only curative option in Fanconi anaemia (FA). We analysed the outcome of children transplanted for FA between 1999 and 2018 in the UK. A total of 94 transplants were performed in 82 patients. Among the donors, 51·2% were matched related donors (MRD) while the remainder were alternative donors. Most patients received a fludarabine-cyclophosphamide (Flu-Cy)-based conditioning regimen (86·6%) and in vivo T-cell depletion with alemtuzumab (69·5%). Five-year overall survival (OS) was 85·4% [70·4-93.2] with MRD, 95·7% [72·9-99.4] with matched unrelated donors (MUD), 44·4% [6·6-78.5] with mismatched unrelated donors (MMUD) and 44·4% [13·6-71.9] with mismatched related donors (MMRD) (P < 0·001). Other factors significantly impacting OS were pre-transplant bone marrow status, source of stem cells, cytomegalovirus (CMV) serostatus, preparation with Flu-Cy, use of total body irradiation (TBI) and alemtuzumab as serotherapy. In multivariate analysis, absence of myelodysplastic syndrome (MDS) or leukaemia, bone marrow as source of stem cells, cytomegalovirus (CMV) other than +/- (Recipient/Donor) and Flu-Cy were protective factors for five-year OS. Five-year chronic graft-versus-host-disease (cGVHD)-free event-free survival was 75·4% with the same risk factors except for CMV serostatus. Five-year non-relapse mortality was 13·8% [7·3-22.3]. Only five patients (6·1%) developed grade II-IV acute GVHD and two patients chronic GVHD. These data confirm the excellent outcome of matched related or unrelated HSCT in children with FA.
引用
- Bernard F, Uppungunduri CRS, Meyer S, et al. Excellent overall and chronic graft-versus-host-disease-free event-free survival in Fanconi anaemia patients undergoing matched related- and unrelated-donor bone marrow transplantation using alemtuzumab-Flu-Cy: the UK experience. Br J Haematol. 2021. PMID: 33855694. doi:10.1111/bjh.17418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。